AMW GmbH is a specialty pharmaceutical company focused on innovative bio-degradable sustained-release drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four marketed products (goserelin & leuprorelin implants, rivastigmine & buprenorphine patches).